Search

Objective To assess the prognostic significance of persistent low-level viraemia (PLV, defined as persistent plasma viral loads of 51–1000 HIV-1 RNA copies/mL for at least 3 months) in patients who had achieved viral suppression on antiretroviral therapy (ART). Methods A retrospective cohort of HIV-infected patients who received ART, were followed-up for ≥12 months, made regular visits to the clinic during which blood tests were performed for an ultrasensitive HIV RNA assay every 3 months, and achieved viral loads <50 copies/mL were evaluated. Virological failure was defined as two consecutive viral load measurements >1000 copies/mL. Results Of 362 patients, 78 (27.5%) experienced PLV. The demographics of patients with and without PLV were similar. PLV occurred at a mean (±standard deviation) of 22.6±16.9 months after ART initiation and lasted for 6.4±3.4 months. During a median follow-up of 29.5 months, patients with PLV had a higher rate of virological failure (39.7% vs 9.2%; P<0.001). The median time to failure was 68.4 months [95% confidence interval (CI) 37.0–99.7] for patients with PLV and >72 months for patients without PLV (log rank test, P<0.001). By Cox regression, patients with PLV had a greater risk of virological failure [hazard ratio (HR) 3.8; 95% CI 2.2–6.4; P<0.001]. Among patients with PLV, a PLV of >400 copies/mL (HR 3.3; 95% CI 1.5–7.1; P=0.003) and a history of ART (HR 2.4; 95% CI 1.0–5.7; P=0.042) predicted virological failure. Conclusions PLV is associated with virological failure. Patients with a PLV >400 copies/mL and a history of ART experience are more likely to experience virological failure. Patients with PLV should be considered for treatment optimization and interventional studies. [ABSTRACT FROM AUTHOR]

There is increasing concern that patients with chronic HIV infection may be at increased risk of nonalcoholic fatty liver disease (NAFLD), which can evolve into nonalcoholic steatohepatitis (NASH) and cirrhosis. Multiple factors have been hypothesized to be necessary for the development and progression of this condition. Potential risk factors, which tend to accumulate in the HIV-positive population, include metabolic derangements, chronic inflammation, hepatitis coinfection, and treatment with certain nucleoside reverse transcriptase inhibitors (NRTIs). HIV-associated conditions such as hyperlactatemia and lipodystrophy frequently overlap with fatty liver disease. The cornerstone of management of HIV-associated fatty liver disease is currently to treat the predominant underlying condition. There is a need for more epidemiologic data to better define the role of comorbidities and drugs in the development of NAFLD. Further work is also needed to elucidate the pathogenesis and to evaluate the therapeutic effect of treating comorbidities and avoiding certain antiretroviral drugs. [ABSTRACT FROM AUTHOR]

A significant proportion of human immunodeficiency virus (HIV) infected patients are coinfected with hepatitis B virus (HBV). Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance. Tenofovir disoproxil fumarate (TDF) is a nucleotide analog with excellent activity in vitro against HBV, which is also active against 3TC-resistant HBV variants. In this 24-week pilot study, the anti-HBV activity of TDF was prospectively evaluated in a cohort of 6 HIV coinfected subjects for whom 3TC and IFN therapy had previously failed. At baseline, all patients were taking 3TC or FTC and were hepatitis B surface antigen and hepatitis B e antigen positive; 4 had cirrhosis. Baseline HBV load was 7.95 log(10) copies/mL. By weeks 12 and 24, HBV load had decreased by 3.1 log(10) copies/mL and 4.3 log(10) copies/mL, respectively. There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals. Copyright © 2002 Infectious Diseases Society of America [ABSTRACT FROM AUTHOR]

As knowledge about HIV continues to grow, so do treatment options. While a cure remains out of reach, disease management can now stall the once inexorable progression from infection to AIDS and death. [ABSTRACT FROM AUTHOR]

Antireroviral therapy is still very much a guessing game, but clear guidance is emerging on two other fronts: heading off opportunistic infections and preventing perinatal transmission. [ABSTRACT FROM AUTHOR]

Chemoprophylaxis for more than a dozen opportunistic infections now allows people with HIV disease to live longer and better lives. Devising an effective regimen is a tough job, but one you can expect to be doing. [ABSTRACT FROM AUTHOR]